within Pharmacolibrary.Drugs.ATC.L;

model L01EX01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.7833333333333333,
    adminDuration  = 600,
    adminMass      = 0.05,
    adminCount     = 1,
    Vd             = 2.23,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011333333333333334,
    Tlag           = 19.8
  );

  annotation(Documentation(
    info ="<html><body><p>Sunitinib is an orally available, multi-targeted receptor tyrosine kinase inhibitor used primarily in the treatment of renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors. It is currently approved and widely used in oncology.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics as described in adults with advanced solid tumors, following oral administration; typical population (no specified restrictions on age or sex); steady-state parameters after repeated dosing.</p><h4>References</h4><ol><li><p>Mueller-Schoell, A, et al., &amp; Kloft, C (2021). Therapeutic drug monitoring of oral targeted antineoplastic drugs. <i>European journal of clinical pharmacology</i> 77(4) 441–464. DOI:<a href=&quot;https://doi.org/10.1007/s00228-020-03014-8&quot;>10.1007/s00228-020-03014-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33165648/&quot;>https://pubmed.ncbi.nlm.nih.gov/33165648</a></p></li><li><p>Szałek, E, et al., &amp; Grześkowiak, E (2013). Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model. <i>Pharmacological reports : PR</i> 65(5) 1383–1390. DOI:<a href=&quot;https://doi.org/10.1016/s1734-1140(13)71497-x&quot;>10.1016/s1734-1140(13)71497-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24399735/&quot;>https://pubmed.ncbi.nlm.nih.gov/24399735</a></p></li><li><p>Kloth, JS, et al., &amp; Mathijssen, RH (2015). Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence. <i>Clinical pharmacokinetics</i> 54(8) 851–858. DOI:<a href=&quot;https://doi.org/10.1007/s40262-015-0239-5&quot;>10.1007/s40262-015-0239-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25647628/&quot;>https://pubmed.ncbi.nlm.nih.gov/25647628</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EX01;
